Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for TTY Biopharm Company Limited (4105:TWSE), powered by AI.
TTY Biopharm Company Limited is currently trading at $73.70. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for TTY Biopharm Company Limited on Alpha Lenz.
TTY Biopharm Company Limited's P/E ratio is 11.8.
“TTY Biopharm Company Limited trades at a P/E of 11.8 (undervalued) with strong ROE of 22.3%. Operating margin of 26.4% indicates strong profitability.”
Ask for details →TTY Biopharm Company Limited is a publicly traded pharmaceutical company specializing in the research, development, manufacture, and sale of pharmaceutical preparations. Established in 1960 and headquartered in Taipei, Taiwan, the company serves Taiwan’s pharmaceuticals and biotechnology sector, focusing primarily on supplying both branded and generic pharmaceutical products. As a mid-sized firm with approximately 342 employees, TTY Biopharm emphasizes innovation within therapeutics, contributing to the healthcare landscape through a diverse portfolio of medicines and treatments. The company has demonstrated robust financial growth, reporting annual revenues exceeding NT$6 billion and steady year-over-year increases in both revenue and net income. TTY Biopharm’s market presence and sustained operational history have positioned it as an influential player within Taiwan’s pharmaceutical industry, underpinning the supply chain and supporting medical needs across the region.
“TTY Biopharm Company Limited trades at a P/E of 11.8 (undervalued) with strong ROE of 22.3%. Operating margin of 26.4% indicates strong profitability.”
Ask for details →TTY Biopharm Company Limited (ticker: 4105) is a company listed on TWSE in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $18.3B.
The current price is 73.7 with a P/E ratio of 11.75x and P/B of 2.53x.
ROE is 22.29% and operating margin is 26.42%. Annual revenue is $6.5B.